97 related articles for article (PubMed ID: 21358206)
21. Significance of pre-treatment immunological parameters in colorectal cancer patients with unresectable metastases to the liver.
Zaloudik J; Lauerova L; Janakova L; Talac R; Simickova M; Nekulova M; Mikulikova I; Kovarik J; Sheard M
Hepatogastroenterology; 1999; 46(25):220-7. PubMed ID: 10228796
[TBL] [Abstract][Full Text] [Related]
22. Liver resection remains a safe procedure after neoadjuvant chemotherapy including bevacizumab: a case-controlled study.
Tamandl D; Gruenberger B; Klinger M; Herberger B; Kaczirek K; Fleischmann E; Gruenberger T
Ann Surg; 2010 Jul; 252(1):124-30. PubMed ID: 20562613
[TBL] [Abstract][Full Text] [Related]
23. [Evaluation of bevacizumab for advanced colorectal cancer].
Naito M; Hoshino S; Noda N; Nakano M; Matsuo K; Yamauchi Y; Shinohara T; Tanaka S; Yamashita Y
Gan To Kagaku Ryoho; 2010 Jan; 37(1):83-8. PubMed ID: 20087037
[TBL] [Abstract][Full Text] [Related]
24. Thromboembolic events in patients with colorectal cancer receiving the combination of bevacizumab-based chemotherapy and erythropoietin stimulating agents.
Roddy JV; Partridge SM; Rockey ML; Pruemer JM; Guo JJ; Desai SJ; Safa MM
Am J Clin Oncol; 2010 Feb; 33(1):36-42. PubMed ID: 19652579
[TBL] [Abstract][Full Text] [Related]
25. [Two radically resected colorectal carcinoma cases with unresectable liver metastasis after adjuvant chemotherapy with bevacizumab].
Sugiyama M; Kakeji Y; Kubo N; Nakanoko T; Fujinaka Y; Ando K; Masuda T; Yagi K; Yoshinaga K; Saeki H; Endo K; Emi Y; Morita M; Maehara Y
Gan To Kagaku Ryoho; 2009 Nov; 36(12):2169-71. PubMed ID: 20037359
[TBL] [Abstract][Full Text] [Related]
26. Decrease in intrahepatic CD56+ lymphocytes in gastric and colorectal cancer patients with liver metastases.
Gulubova M; Manolova I; Kyurkchiev D; Julianov A; Altunkova I
APMIS; 2009 Dec; 117(12):870-9. PubMed ID: 20078551
[TBL] [Abstract][Full Text] [Related]
27. Inhibition of dendritic cell maturation by the tumor microenvironment correlates with the survival of colorectal cancer patients following bevacizumab treatment.
Michielsen AJ; Noonan S; Martin P; Tosetto M; Marry J; Biniecka M; Maguire AA; Hyland JM; Sheahan KD; O'Donoghue DP; Mulcahy HE; Fennelly D; Ryan EJ; O'Sullivan JN
Mol Cancer Ther; 2012 Aug; 11(8):1829-37. PubMed ID: 22675042
[TBL] [Abstract][Full Text] [Related]
28. Circulating endothelial cells and their apoptotic fraction are mutually independent predictive biomarkers in Bevacizumab-based treatment for advanced colorectal cancer.
Manzoni M; Mariucci S; Delfanti S; Rovati B; Ronzoni M; Loupakis F; Brugnatelli S; Tinelli C; Villa E; Falcone A; Danova M
J Cancer Res Clin Oncol; 2012 Jul; 138(7):1187-96. PubMed ID: 22419441
[TBL] [Abstract][Full Text] [Related]
29. Changes in Immunological Status in Patients With Metastatic Colorectal Cancer Treated With First-line Chemoimmunotherapy.
Yamada T; Yoshida Y; Maeda T; Yoshimatsu G; Aisu N; Yamashita K; Komono A; Kajitani R; Matsumoto Y; Nagano H; Naito K; Yasumoto K; Takimoto R; Kamigaki T; Goto S; Yoshimura F; Sakata N; Kodama S; Hasegawa S
Anticancer Res; 2020 Aug; 40(8):4763-4771. PubMed ID: 32727803
[TBL] [Abstract][Full Text] [Related]
30. Unresectable metastatic liver disease: new therapeutical alternatives.
Lygidakis NJ
Hepatogastroenterology; 1999 May; 46 Suppl 1():1297-305. PubMed ID: 10429978
[No Abstract] [Full Text] [Related]
31. Molecular mechanisms and clinical applications of angiogenesis.
Carmeliet P; Jain RK
Nature; 2011 May; 473(7347):298-307. PubMed ID: 21593862
[TBL] [Abstract][Full Text] [Related]
32. Interaction of immune cells with renal cancer development: Mendelian randomization (MR) study.
Lu Z; Yin Y; Rao T; Xu X; Zhao K; Liu Z; Qin C; Tang M
BMC Cancer; 2024 Apr; 24(1):439. PubMed ID: 38594655
[TBL] [Abstract][Full Text] [Related]
33. Targeting the immune microenvironment for ovarian cancer therapy.
Blanc-Durand F; Clemence Wei Xian L; Tan DSP
Front Immunol; 2023; 14():1328651. PubMed ID: 38164130
[TBL] [Abstract][Full Text] [Related]
34. The effects of anti-PD-L1 monoclonal antibody on the expression of angiogenesis and invasion-related genes.
Babahan C; Abdi Abgarmi S; Sonugür FG; Öçal M; Akbulut H
Turk J Biol; 2023; 47(4):262-275. PubMed ID: 38152616
[TBL] [Abstract][Full Text] [Related]
35. Harnessing tumor immunity with cytotoxics: T cells monitoring in mice bearing lung tumors treated with anti-VEGF and pemetrexed-cisplatin doublet.
Sicard G; Protzenko D; Giacometti S; Barlési F; Ciccolini J; Fanciullino R
Br J Cancer; 2023 Oct; 129(9):1373-1382. PubMed ID: 37524968
[TBL] [Abstract][Full Text] [Related]
36. Enhancing immunotherapy response in melanoma: myeloid-derived suppressor cells as a therapeutic target.
Ozbay Kurt FG; Lasser S; Arkhypov I; Utikal J; Umansky V
J Clin Invest; 2023 Jul; 133(13):. PubMed ID: 37395271
[TBL] [Abstract][Full Text] [Related]
37. Potential Immunotherapy Targets for Liver-Directed Therapies, and the Current Scope of Immunotherapeutics for Liver-Related Malignancies.
Charles J; Vrionis A; Mansur A; Mathias T; Shaikh J; Ciner A; Jiang Y; Nezami N
Cancers (Basel); 2023 May; 15(9):. PubMed ID: 37174089
[TBL] [Abstract][Full Text] [Related]
38. Immunosuppressive effects of vascular endothelial growth factor.
Ribatti D
Oncol Lett; 2022 Oct; 24(4):369. PubMed ID: 36238855
[TBL] [Abstract][Full Text] [Related]
39. Immunosuppressive tumor microenvironment modulation by chemotherapies and targeted therapies to enhance immunotherapy effectiveness.
Barnestein R; Galland L; Kalfeist L; Ghiringhelli F; Ladoire S; Limagne E
Oncoimmunology; 2022; 11(1):2120676. PubMed ID: 36117524
[TBL] [Abstract][Full Text] [Related]
40. How Chemotherapy Affects the Tumor Immune Microenvironment: A Narrative Review.
Merlano MC; Denaro N; Galizia D; Ruatta F; Occelli M; Minei S; Abbona A; Paccagnella M; Ghidini M; Garrone O
Biomedicines; 2022 Jul; 10(8):. PubMed ID: 36009369
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
